{
  "Country": "DK",
  "PICOs": [
    {
      "Population": "Patients with KRAS p.G12C mutation and advanced NSCLC",
      "Intervention": "New medicine under assessment",
      "Comparator": "Sotorasib",
      "Outcomes": "Overall survival (OS) and progression-free survival (PFS)"
    },
    {
      "Population": "Patients with KRAS-mutant advanced NSCLC",
      "Intervention": "New medicine under assessment",
      "Comparator": "Docetaxel",
      "Outcomes": "Overall survival (OS) and progression-free survival (PFS)"
    },
    {
      "Population": "Patients with KRAS-mutant advanced NSCLC who have received prior therapy",
      "Intervention": "New medicine under assessment",
      "Comparator": "Docetaxel alone",
      "Outcomes": "Progression-free survival (PFS)"
    }
  ]
}